item management s discussion and analysis of financial condition and results of operations this report contains forward looking statements which involve risks and uncertainties 
such statements are subject to certain factors which may cause the company s plans and results to differ significantly from plans and results discussed in forward looking statements 
factors that might cause or contribute to such differences include  but are not limited to  those discussed in important factors regarding forward looking statements attached hereto as exhibit overview since its inception in january  alexion has devoted substantially all of its resources to its drug discovery  research and product development programs 
to date  alexion has not received any revenues from the sale of products 
the company has been unprofitable since inception  and expects to incur substantial and increasing operating losses for the next several years due to expenses associated with product research and development  preclinical and clinical testing  regulatory activities and manufacturing development and scale up 
as of july   the company has an accumulated deficit of million 
the company s plan is to develop and commercialize on its own those product candidates for which the clinical trial and marketing requirements can be funded by the company 
for certain of the company s c inhibitor and apogen products for which greater resources will be required  alexion s strategy is to form corporate partnerships with major pharmaceutical companies for product development and commercialization 
alexion has entered into a strategic alliance with us surgical with respect to the company s unigraft program and intends to seek additional strategic alliances with major pharmaceutical companies although no assurances can be given that such alliances will be successfully entered into 
the company recognizes research and development revenues when the development expenses are incurred and the related work is performed under the terms of the contracts 
any revenue contingent upon future expenditures by the company is deferred and recognized as the expenditures are incurred 
any revenues contingent upon the achievement of milestones will be recognized when the milestones are achieved 
results of operations years ended july    and the company earned grant  license  and contract research revenues of million  million  and million for the fiscal years ended july    and  respectively 
the increase in fiscal was primarily due to revenues the company received from us surgical of million which represented a one time license fee in connection with the companies collaborative research and development agreement 
the increase in fiscal revenues as compared to fiscal resulted principally from company s revenues received from gti novartis of million which represented a one time upfront license fee of  and contract research and development revenues of  the revenues in fiscal resulted from the receipt of funds from us surgical of approximately million from a collaborative research and development agreement and the  in funding received from the nist s atp grant 
see item business strategic alliances  collaborations and licenses 
during the fiscal years ended july    and  the company expended million  million  and million  respectively  on research and development activities 
increases in research and development spending were primarily attributable to the company s clinical trials of the company s lead c inhibitor product candidate and expanded preclinical development of the company s research programs which included the manufacturing product development for the company s c inhibitor and apogen product candidates 
see item business alexion s drug development programs  cardiopulmonary bypass surgery 
the company s general and administrative expenses were million  million  and million for the fiscal years ended july   and  respectively 
the decrease in general and administrative expenses in fiscal was primarily related to lower legal and patent costs in fiscal as compared to fiscal the increase in general and administrative expenses in fiscal as compared to fiscal consisted of  related to increased expenses related to facilities expansion  other employee benefits  and increased travel and administrative costs attributable to increased clinical  regulatory  and scientific conference activities 
the remaining balance  of the increase was related to increased costs for outside professional services and insurance related to business development  recruiting  patent and legal activities as a public company 
other income expense  net  representing primarily net investment income  was million   and  for the fiscal years ended july    and  respectively 
the increase over the past three years was due primarily to greater investment income from higher cash balances available for investment during fiscal year as compared to the prior two fiscal years 
as a result of the above factors  the company had incurred net losses of million  million  and million for the fiscal years ended july   and  respectively 
liquidity and capital resources since its inception through july   the company has financed its operations and capital expenditures primarily through its private placements and initial public offering of equity securities resulting in approximately million of aggregate net proceeds 
the company has financed the purchase of certain equipment through million of secured notes payable to a financing institution and  of capital lease obligations 
through july   the company has also received approximately million in research and development support under its collaborations with us surgical and gti novartis 
the company has also received million from its sbir grants from the nih and million under the atp grant from nist 
in addition  the company and us surgical were awarded in november  a three year million cooperative agreement under another atp grant from nist 
all of the foregoing proceeds have been used to fund operating activities of approximately million and investments of approximately million and  in equipment and licensed technology rights and patents  respectively  through july  as of july   the company had working capital of approximately million and total cash  cash equivalents  and marketable securities amounted to approximately million 
at july   approximately million of cash is held in short term highly liquid investments with original maturities of less than three months 
the company increased its cash and cash equivalents by million during the twelve months ended july  this increase resulted principally from cash flows provided by financing activities which provided million from the net proceeds received from the issuance of common stock offset by  in repayments of notes payable  capital equipment purchases of approximately million  and the million cash outflow used in operating activities primarily as a result of million of operating losses 
the company leases its administrative and research and development facilities under three operating leases expiring in december  june  and march the company is currently continuing the leases which expired in december and june on a month to month basis while discussions for lease extensions are on going 
the company is obligated to make payments pursuant to certain of its licensing and research and development agreements 
the company is scheduled to pay   and  assuming no termination of these agreements during the fiscal years ending july   and  respectively 
in addition  the company is obligated to make certain future milestone payments to certain of its licensors  contingent upon receiving regulatory approval on certain patent issuances as well as on certain of the company s possible product plas  if and when approved 
see item business strategic alliances  collaborations and licenses 
the company anticipates that its existing available capital resources and interest earned on available cash and marketable securities should be sufficient to fund its operating expenses and capital requirements as currently planned for at least the next eighteen months 
while the company currently has no material commitments for capital expenditures  the company s future capital requirements will depend on many factors  including the progress of the company s research and development programs  progress in clinical trials  the time and costs involved in obtaining regulatory approvals  the costs involved in obtaining and enforcing patents and any necessary licenses  the ability of the company to establish development and commercialization relationships  and the costs of manufacturing scale up 
see item business alexion s drug development strategy 
the company expects to incur substantial additional costs  including costs associated with research  preclinical and clinical testing  manufacturing process development  and additional capital expenditures associated with facility expansion and manufacturing requirements in order to commercialize its products currently under development 
the company will need to raise substantial additional funds through additional financings including public or private equity offerings and collaborative research and development arrangements with corporate partners 
there can be no assurance that funds will be available on terms acceptable to the company  if at all  or that discussions with potential collaborative partners will result in any agreements on a timely basis  if at all 
the unavailability of additional financing could require the company to delay  scale back or eliminate certain of its research and product development programs or to license third parties to commercialize products or technologies that the company would otherwise undertake itself  any of which could have a material adverse effect on the company 
as of july   the company had approximately million and million of net operating loss and tax credit carryforwards for tax reporting purposes  respectively  which expire commencing in fiscal the tax reform act of the tax act contains certain provisions that may limit the company s ability to utilize net operating loss and tax credit carryforwards in any given year if certain events occur  including cumulative changes in ownership interests in excess of over a three year period 
there can be no assurance that ownership changes in future periods will not significantly limit the company s use of its existing net operating loss and tax credit carryforwards 
year the year or yk issue affects computer and information technology it systems  as well as non it systems which include embedded technology such as micro processors and micro controllers or micro chips that have date sensitive programs that may not properly recognize the year systems that do not properly recognize such information could generate inaccurate data or cause a system to fail  resulting in business interruption 
the company is currently developing a plan to provide measured assurances that its computer and it systems  non it systems  including embedded systems such as hvac heating  ventilation and air conditioning systems and other analytical instruments and equipment  and those of third parties which have a material relationship with the company are or will be yk compliant 
the company expects to complete in november a comprehensive inventory and assessment of its existing it and non it systems and those of third parties  as well as planned and anticipated systems  and third parties services which the company may purchase or use 
assessment will include identifying critical systems internal and external including third parties in order to formulate a remediation and verification plan 
the company currently believes that remediation and verification  which include obtaining written assurances from key vendors and suppliers  as well as testing  will be complete by july the company believes  based on preliminary information  that the costs associated with remediation and verification to become yk compliant will not have a material adverse impact on the company s financial position  results of operations  or cash flow 
in the event that the company s yk compliance plan is not successfully implemented  the company may experience temporary disruptions of the company s clinical trial sites as well as external contract manufacturing of the company s therapeutic products presuming broad yk compliance by general service providers such as utilities  telephone  data transfer  and other government and private entities 
while the company has not yet developed contingency plans for such event  the company expects to prepare such plans by august although the company has taken steps to address the yk problem  there can be no assurance that the failure of the company and or its material third parties to timely attain yk compliance or that the failures and or the impacts of broader compliance failures by telephone  mail  data transfer or other utility or general service providers or government or private entities will not have a material adverse effect on the company 
further  there can be no assurance that the costs associated with achieving such compliance or any failure to become yk compliant will not be material to the company s financial position  its results of operations  or its cash flow 
item a 
qualitative and quantitative disclosures about market risk not applicable 

